Abstract 1879P
Background
Cancer affects many aspects of life and can have negative consequences such as reducedː health and quality of life and mental disorders. Cancer patients face most of the stressors associated with diagnosis and treatment. The aim of this study is investigating the effect of family support on the mental health of patients with breast Cancer.
Methods
This cross-sectional study examined 70 breast cancer patients who were referred within 6 months to Imam Khomeini and Shohadah Ha* Tir Hospitals for radiotherapy, chemotherapy or follow- up treatment. In terms of mental health, these patients were assessed using the criteria of hospital anxiety and depression and distress thermometer, and the level of family support using the McMaster Family Assessment Device and attachment style criteria. The psychiatric interview with the patients was conducted by the psychiatric resident and all questionnaires were completed by her in face-to-face interviews or video calls with the patient. Before the start of the study, all patients gave written informed consent. The Family Support Questionnaire contains 60 questions that identify the structural, professional, and interactive characteristics of the family. This questionnaire has 7 subscales.
Results
The mean (standard deviation) of the total score on the Family Support Questionnaire for the subjects studied was 15.7 (2.96) with a range of 9.87 to 21.06. the mean (standard deviation) of anxiety and depression scores were 9.68 (5.34) and 8.34 (4.41), respectively. the results show that increasing the score on anxiety and depression significantly increases family support and its sub-comparisons.
Conclusions
The study revealed that the mean scores of the depression and anxiety in breast cancer patients is more than normal limitation. The results showed that decreasing family support and its sub- comparisons (an increase in the score indicates an unhealthy situation) significantly increases anxiety and depression in these individuals.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Iran University of Medical Sciences.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05